Emerging drugs to replace current leaders in first-line therapy for breast cancer (Q36580598)

15 August 2017

1 reference

title

Emerging drugs to replace current leaders in first-line therapy for breast cancer (English)

1 reference

15 August 2017

Michael C Cox

1

1 reference

15 August 2017

Tu D Dan

series ordinal

2

1 reference

15 August 2017

Sandra M Swain

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

489-501

1 reference

15 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Predicting the survival of patients with breast carcinoma using tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The role of taxanes in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Angiogenesis and prostate cancer tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Prognostic value of vascular endothelial growth factor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Pharmacogenetics for individualized cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.489

10.1517/14728214.11.3.489

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference